Image of a chemical structure

Developing transformative medicines for neurological and mental health disorders

CNS drug discovery. CNS drug discovery. CNS drug discovery.
inspired by nature. powered by AI.
Image of neuron
Our Core

Promoting neuroplasticity.

Our lead R&D program focuses on activating the TrkB receptor pathway, which promotes neuronal survival and synaptic plasticity. Our lead candidate OT-003 and fast follower OT-1xx series have generated compelling data in a variety of CNS disorders with significant unmet need.

Facts and figures

Pushing for a better tomorrow.

57+ Mn

People suffer from dementia worldwide

... with an expected growth to over 150 Mn by 2050. This example of growing patient populations in CNS disorders shows the urgent need for new treatments addressing neurological and neuropsychiatric diseases.

24+ Mn

People globally suffer from schizophrenia

...with one-third being treatment resistant.

~80m

Patients worldwide suffer from Glaucoma

...for which there is no cure.

c65%

of people with Major Depressive Disorder

...do not fully recover by using antidepressant medication

picture of green hills and landscape

Pangea's scaleable pipeline of CNS drugs

Our lead asset OT-003 shows compelling efficacy across neurological disease models and we are planning to start our Phase 1 studies in 2025. In addition, we created a pipeline of next-generation TrkB activators. These maintain OT-003's comelling pharmacology and possess a range of PK properties, enabling progression in distinct neurological disorders

Subscribe to our newsletter

We send our newsletter regularly, sharing news and trends around Pangea and our research space.

Thank you! We have sent you an email to confirm your subscription!
Oops! Something went wrong while submitting the form.